Janux Therapeutics Inc. (JANX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Janux Therapeutics Inc. (JANX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

45.33

0.27 (0.60%)

At close: Jan 14, 2025, 3:59 PM

45.35

0.04%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	41.75
Market Cap	2.62B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.17
PE Ratio (ttm)	-38.74
Forward PE	n/a
Analyst	Buy

Ask	47.99
Volume	795,131
Avg. Volume (20D)	1,093,434
Open	45.33
Previous Close	45.06
Day's Range	44.17 - 46.15
52-Week Range	7.79 - 71.71
Beta	undefined

About JANX

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 11, 2021

Employees 76

Stock Exchange NASDAQ

Ticker Symbol JANX

Website https://www.januxrx.com

Analyst Forecast

According to 10 analyst ratings, the average rating for JANX stock is "Buy." The 12-month stock price forecast is $70, which is an increase of 54.42% from the latest price.

Buy 90.00%

Hold 10.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Janux Therapeutics Inc. is scheduled to release its earnings on Mar 7, 2025, during market hours.
Analysts project revenue of $490.00K, reflecting a -80.09% YoY shrinking and earnings per share of -0.45, making a 80.00% increase YoY.

Why Price Moved

1 month ago · Source

+11.64%

Janux Therapeutics shares are trading higher after... Unlock content with Pro Subscription

1 month ago · Source

+48.98%

Janux Therapeutics shares are trading higher after the company announced updated interim clinical data for its JANX007 program in prostate cancer.

News

1 week ago · seekingalpha.com

Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data

Janux Therapeutics' leading candidate, JANX007, shows high efficacy and safety in Phase 1 trials for metastatic castration-resistant prostate cancer, targeting a multi-billion dollar TAM. Janux's TRAC...

1 week ago · seekingalpha.com

Best-Performing Stocks Of 2024

1 month ago · businesswire.com

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...

1 month ago · businesswire.com

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

1 month ago · fool.com

Why Janux Therapeutics Crushed the Market Today

News of an analyst's price-target hike plus a new round of capital-raising were the sparks that ignited Janux Therapeutics (JANX 11.65%) stock on Wednesday. The clinical-stage biotech's share price en...

1 month ago · zacks.com

JANX Stock Hits Record High on Prostate Cancer Study Data

An early-stage study data shows that treatment with Janux's JANX007 generates deep and durable efficacy responses in heavily pretreated patients with mCRPC.

1 month ago · businesswire.com

Janux Therapeutics Announces Proposed Public Offering

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Proposed Public Offering.

1 month ago · benzinga.com

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst

On Monday, Janux Therapeutics, Inc. JANX revealed updated interim clinical data for its JANX007 clinical program.

1 month ago · barrons.com

Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results

The therapeutics company reports encouraging Phase 1 trial results for a novel cancer treatment.

1 month ago · businesswire.com

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Announces Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC.

1 month ago · businesswire.com

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Host Virtual Event.

1 month ago · seekingalpha.com

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

Janux Therapeutics' TRACTr and TRACIr platforms show promise in targeting cancer cells while minimizing off-target effects and improving drug half-life. Lead candidate JANX007 demonstrates strong PSA ...

2 months ago · businesswire.com

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $JANX--3Q24 Earnings Release.